FORM 4	
--------	--

Check this box if no longer
subject to Section 16. Form 4 or
Form 5 obligations may
continue. See Instruction 1(b).

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549

OMB APPROVAL OMB Number: 3235-0287 Estimated average burden hours per response... 0.5

# STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person +	2. Issuer Name and Ticker or Trading Symbol	5. Relationship of Reporting Person(s) to Issuer				
Zhou Rong	Amphastar Pharmaceuticals, Inc. [ AMPH ]	(Check all applicable)				
(Last) (First) (Middle)	3. Date of Earliest Transaction (MM/DD/YYYY)	X_Officer (give title below) Other (specify below) EVP, Production Center				
C/O AMPHASTAR	6/15/2023					
PHARMACEUTICALS, INC., 11570 6TH STREET						
(Street)	4. If Amendment, Date Original Filed (MM/DD/YYYY)	6. Individual or Joint/Group Filing (Check Applicable Line)				
RANCHO CUCAMONGA, CA 91730		X Form filed by One Reporting Person Form filed by More than One Reporting Person				
(City) (State) (Zip)	Rule 10b5-1(c) Transaction Indication					
	$\Box$ Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.					

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

	Execution	(Instr. 8) Disposed of (D)			of (D)			6. Ownership Form: Direct (D)	Beneficial Ownership
		Code	v	Amount	(A) or (D)	Price		or Indirect (I) (Instr. 4)	(Instr. 4)
6/15/2023		М		13575	Α	\$14.40	101888	D	
6/15/2023		S		5000	D	\$51.7893 <u>(1)</u>	96888	D	
6/15/2023		М		4631	Α	\$14.95	101519	D	
6/15/2023		М		1171	Α	\$16.19	102690	D	
							99668	I	See footnote (2
							5000	I	See footnote (
	6/15/2023 6/15/2023 6/15/2023	6/15/2023         6/15/2023           6/15/2023         6/15/2023	Execution Date, if any         (Instr. 8)           6/15/2023         M           6/15/2023         S           6/15/2023         M	Execution Date, if any (Instr. 8) Code V 6/15/2023 M 6/15/2023 S 6/15/2023 M	Execution Date, if any         (Instr. 8)         Disposed (Instr. 3,           Code         V         Amount           6/15/2023         M         13575           6/15/2023         S         5000           6/15/2023         M         4631	Execution Date, if any         (Instr. 8)         Disposed of (D) (Instr. 3, 4 and 5)           Code         V         Amount         (A) or (D)           6/15/2023         M         13575         A           6/15/2023         S         5000         D           6/15/2023         M         4631         A	Execution Date, if any         (Instr. 8)         Disposed of (D) (Instr. 3, 4 and 5)           Code         V         Amount         (A) or (D)           6/15/2023         M         13575         A         \$14.40           6/15/2023         S         5000         D         \$51.7893 (I)           6/15/2023         M         4631         A         \$14.95	Execution Date, if any         (Instr. 8)         Disposed of (D) (Instr. 3, 4 and 5)         Following Reported Transaction(s) (Instr. 3 and 4)           6/15/2023         M         V         Amount (D)         Price         Price           6/15/2023         M         I         13575         A         \$14.40         101888           6/15/2023         S         5000         D         \$51.7893 \ldots         96888           6/15/2023         M         4631         A         \$14.95         101519           6/15/2023         M         1171         A         \$16.19         102690           6/15/2023         M         I         I171         A         \$16.19         99668	Execution Date, if any(Instr. 8)Disposed of (D) (Instr. 3, 4 and 5)Following Reported Transaction(s)Ownership Form: Direct (D) or Indirect6/15/2023M13575A\$14.40101888D6/15/2023M13575A\$14.40101888D6/15/2023M4631A\$14.95101519D6/15/2023M1171A\$16.19102690D6/15/2023M1171A\$16.19102690D

#### Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivate Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Trans. Date		4. Trans. Code (Instr. 8)		Derivat Acquire Dispose	Number of berivative Securities cquired (A) or bisposed of (D) nstr. 3, 4 and 5)		nd Expiration Date Securities Underlying Derivative Security			piration Date Securities Underlying Derivative derivat Derivative Security (Instr. 3 and 4) (Instr. 5) Ownee		piration Date Securities Underlying Derivative Derivative Security Security		derivative Securities Beneficially	Ownership Form of	11. Nature of Indirect Beneficial Ownership (Instr. 4)
	Security			Code	v	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares		Reported Transaction(s)	or Indirect				
Employee Stock Option (right to buy)	\$14.40	6/15/2023		М			13575	( <u>4)</u>	4/14/2024	Common Stock	13575	\$0	4316	D				
Employee Stock Option (right to buy)	\$14.95	6/15/2023		М			4631	( <u>4)</u>	3/26/2025	Common Stock	4631	\$0	13893	D				
Employee Stock Option (right to buy)	\$16.19	6/15/2023		М			1171	<u>(4)</u>	6/15/2025	Common Stock	1171	\$0	3514	D				

#### **Explanation of Responses:**

- (1) The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from \$51.74 to \$51.88, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price.
- (2) The shares are held of record by the Zhou Family Trust for which the reporting person serves as a trustee.
- (3) The shares are held of record by the reporting person's spouse.
- (4) Shares subject to the option are fully vested and immediately exercisable.

### **Reporting Owners**

Poperting Owner Name / Address	Relationships							
Reporting Owner Name / Address	Director	10% Owner	Officer	Other				
Zhou Rong								
C/O AMPHASTAR PHARMACEUTICALS, INC.			EVP, Production Center					
11570 6TH STREET			EVF, Frounction Center					
RANCHO CUCAMONGA, CA 91730								

### Signatures

/s/ Eva Wen, by power of attorney	6/20/2023
-----------------------------------	-----------

\*\*Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

\* If the form is filed by more than one reporting person, see Instruction 4(b)(v).

\*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.